Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences (Nasdaq: KOD) has announced its participation in two major scientific conferences where it will present Phase 1b APEX study data for KSI-101, its bispecific trap-antibody targeting macular edema secondary to inflammation (MESI).
Dr. Charles Wykoff will present the findings at the 25th EURetina Congress in Paris on September 5, 2025, and at The Retina Society 58th Annual Scientific Meeting in Chicago on September 13, 2025. The presentations will focus on KSI-101's dual mechanism of inhibiting both interleukin-6 and vascular endothelial growth factor. Both presentations will be made available on Kodiak's investor relations website.
Harbour BioMed (HKEX: 02142) reported strong 2025 interim results, with total revenue reaching $101.3 million, up 327% year-over-year, and net profit soaring 51-fold to $73.0 million. The company's cash position strengthened to $320 million, a 92% increase from year-end 2024.
Key developments include the BLA acceptance for batoclimab by NMPA for gMG treatment, strategic collaborations with AstraZeneca ($105M equity investment), Windward Bio for HBM9378, and Otsuka for HBM7020. The company advanced multiple clinical-stage programs including porustobart and HBM1020, while expanding its next-generation portfolio with HBM7004 and HBM7020.
The company launched Élancé Therapeutics for obesity treatment and strengthened its platform potential through Nona Biosciences, establishing multiple global partnerships and introducing the AI-assisted Hu-mAtrIx™ drug discovery engine.
Kodiak Sciences (NASDAQ:KOD), a precommercial retina-focused biotech company, will present its glaucoma pipeline programs at the American Chemical Society Fall 2025 Meeting on August 19, 2025, in Washington, D.C.
The company is developing dual-mechanism therapies using its Antibody Biopolymer Conjugate Drug (ABCD) platform. The treatment combines a NLRP3 inhibitor targeting neuroinflammation with an IOP-lowering agent, delivered via quarterly intravitreal injection. Additionally, Kodiak is advancing its VETi™ program, an AI-enabled wearable headset designed to improve clinical trial testing efficiency and accuracy.
Kodiak Sciences (NASDAQ: KOD) reported Q2 2025 financial results and business updates, highlighting progress across its late-stage clinical pipeline. The company's three key assets - tarcocimab, KSI-501, and KSI-101 - are advancing with multiple Phase 3 readouts expected between 1Q 2026 and 1Q 2027.
Notable highlights include promising KSI-101 Phase 1b data in MESI patients, showing rapid anatomical improvements and >90% achieving dryness by week 8. Financially, Kodiak reported a net loss of $54.3 million ($1.03 per share) and ended Q2 with $104.2 million cash, expected to fund operations into 2026. R&D expenses increased to $42.8 million, while G&A expenses decreased to $12.8 million.
Kodiak Sciences (NASDAQ: KOD), a precommercial retina-focused biotechnology company, will host a virtual investor R&D Day on July 16, 2025, from 4:00 PM to 5:30 PM ET. The event will showcase the company's three late-phase clinical assets - tarcocimab, KSI-501, and KSI-101 - with presentations from senior leadership and industry experts.
The company's ABC Platform® uses molecular engineering to combine protein-based and chemistry-based therapies for treating retinal diseases. All three clinical assets are targeting Phase 3 topline data in 2026. The event will be accessible via webcast, with recording available 24 hours after the presentation.
Kodiak Sciences (NASDAQ:KOD) announced its participation in the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, where management and key opinion leaders will present highlights of KSI-101, their investigational treatment for macular edema secondary to inflammation (MESI).
KSI-101 is a first-in-class bispecific intravitreal biologic designed to simultaneously target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). The presentation will address MESI pathophysiology, current treatment limitations, and clinical data for KSI-101. The breakfast symposium is scheduled for June 27, 2025, at 7:00 AM BRT.
Kodiak Sciences (KOD) reported its Q1 2025 financial results and business updates. The company ended Q1 with $138.9 million in cash, expected to fund operations into 2026. The quarter saw a net loss of $57.5 million ($1.09 per share), compared to $43.0 million ($0.82 per share) in Q1 2024. R&D expenses increased to $43.6 million from $29.9 million year-over-year, while G&A expenses slightly decreased to $15.4 million.
The company is advancing as a precommercial stage retina-focused biotech with three Phase 3 assets targeting topline data in 2026. Kodiak plans to host an Investor R&D Update on July 16, 2025, featuring updates on their pipeline including Tarcocimab (GLOW2 and DAYBREAK studies), KSI-501, and KSI-101's APEX Phase 1b trial results.
Kodiak Sciences (KOD) has reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline. The company ended Q4 2024 with $168.1 million in cash, expected to support operations into 2026. The Q4 net loss was $44.1 million ($0.84 per share), compared to $59.5 million in Q4 2023.
Key developments include two Phase 3 studies for tarcocimab: GLOW2 and DAYBREAK, with topline data expected in 1Q and 2Q 2026 respectively. The company plans to file a single BLA in 2026 for wet AMD, retinal vein occlusion, and diabetic retinopathy indications. KSI-501 is being evaluated in the DAYBREAK study, while KSI-101 received FDA Orphan Drug Designation and is progressing in the APEX Phase 1b trial.
R&D expenses decreased to $31.8 million in Q4 2024 from $46.6 million in Q4 2023, while G&A expenses reduced to $14.4 million from $16.7 million year-over-year.